Skip to main content
. 2016 Jan-Apr;9(1):44–48. doi: 10.4103/0974-620X.176100

Figure 1.

Figure 1

A comparison of the changes in the macular thickness in treated and untreated eyes of the same patients, before (baseline) and at 4 weeks after the intravitreal bevacizumab and ranibizumab injections. Note that a statistically significant decrease in the central subfield macular thickness was seen with the bevacizumab administration, but not with the ranibizumab. μm: Microns